Induction treatment with alemtuzumab combined with polychemotherapy containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) followed by Alemtuzumab maintenance in patients with T-Cell prolymphocytic leukaemia (T-PLL): first analysis of a prospective multicenter phase-II-trial (T-PLL2) conducted by the German CLL study group (GCLLSG)
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Article (Journal) Conference Paper |
| Language: | English |
| Published: |
2014
|
| In: |
Blood
Year: 2014, Volume: 124, Issue: 21 |
| ISSN: | 1528-0020 |
| Online Access: | Verlag, kostenfrei, Volltext: https://ashpublications.org/blood/article/124/21/1999/89928/Induction-Treatment-with-Alemtuzumab-Combined-with
|
| Author Notes: | Natali Pflug, Georg Hopfinger, Paula Cramer, Alexandra Schrader, Nicole Weit, Rita Meister, Miriam Thiel, Tanja Annolleck, Anne Westermann, Till M Seiler, Thorsten Zenz, Jan Duerig, Jasmin Bahlo, Karl-Anton Kreuzer, Stephan Stilgenbauer, Anna-Maria Fink, Barbara Eichhorst, Michael Hallek, Marco Herling |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1505229804 | ||
| 003 | DE-627 | ||
| 005 | 20241002090244.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 150709s2014 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1505229804 | ||
| 035 | |a (DE-576)43522980X | ||
| 035 | |a (DE-599)BSZ43522980X | ||
| 035 | |a (OCoLC)1340701277 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 245 | 0 | 0 | |a Induction treatment with alemtuzumab combined with polychemotherapy containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) followed by Alemtuzumab maintenance in patients with T-Cell prolymphocytic leukaemia (T-PLL) |b first analysis of a prospective multicenter phase-II-trial (T-PLL2) conducted by the German CLL study group (GCLLSG) |c Natali Pflug, Georg Hopfinger, Paula Cramer, Alexandra Schrader, Nicole Weit, Rita Meister, Miriam Thiel, Tanja Annolleck, Anne Westermann, Till M Seiler, Thorsten Zenz, Jan Duerig, Jasmin Bahlo, Karl-Anton Kreuzer, Stephan Stilgenbauer, Anna-Maria Fink, Barbara Eichhorst, Michael Hallek, Marco Herling |
| 264 | 1 | |c 2014 | |
| 300 | |a 1 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.07.2015 | ||
| 700 | 1 | |a Pflug, Natali |d 1980- |0 (DE-588)142740306 |0 (DE-627)638925037 |0 (DE-576)333134567 |4 oth | |
| 700 | 1 | |a Zenz, Thorsten |d 1970- |0 (DE-588)114963738 |0 (DE-627)577184202 |0 (DE-576)180278266 |4 oth | |
| 773 | 0 | 8 | |i In |t Blood |d Washington, DC : American Society of Hematology, 1946 |g 124(2014,21) Artikel-Nr. 74529, 1 S. |h Online-Ressource |w (DE-627)266886647 |w (DE-600)1468538-3 |w (DE-576)075961938 |x 1528-0020 |7 nnas |a Induction treatment with alemtuzumab combined with polychemotherapy containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) followed by Alemtuzumab maintenance in patients with T-Cell prolymphocytic leukaemia (T-PLL) first analysis of a prospective multicenter phase-II-trial (T-PLL2) conducted by the German CLL study group (GCLLSG) |
| 773 | 1 | 8 | |g volume:124 |g year:2014 |g number:21 |g extent:1 |a Induction treatment with alemtuzumab combined with polychemotherapy containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) followed by Alemtuzumab maintenance in patients with T-Cell prolymphocytic leukaemia (T-PLL) first analysis of a prospective multicenter phase-II-trial (T-PLL2) conducted by the German CLL study group (GCLLSG) |
| 856 | 4 | 0 | |u https://ashpublications.org/blood/article/124/21/1999/89928/Induction-Treatment-with-Alemtuzumab-Combined-with |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20150709 | ||
| 993 | |a ConferencePaper | ||
| 994 | |a 2014 | ||
| 998 | |g 114963738 |a Zenz, Thorsten |m 114963738:Zenz, Thorsten |p 11 | ||
| 999 | |a KXP-PPN1505229804 |e 2848415436 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Pflug","given":"Natali","display":"Pflug, Natali","role":"oth"},{"display":"Zenz, Thorsten","role":"oth","family":"Zenz","given":"Thorsten"}],"title":[{"title_sort":"Induction treatment with alemtuzumab combined with polychemotherapy containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) followed by Alemtuzumab maintenance in patients with T-Cell prolymphocytic leukaemia (T-PLL)","subtitle":"first analysis of a prospective multicenter phase-II-trial (T-PLL2) conducted by the German CLL study group (GCLLSG)","title":"Induction treatment with alemtuzumab combined with polychemotherapy containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) followed by Alemtuzumab maintenance in patients with T-Cell prolymphocytic leukaemia (T-PLL)"}],"note":["Gesehen am 09.07.2015"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1505229804","language":["eng"],"name":{"displayForm":["Natali Pflug, Georg Hopfinger, Paula Cramer, Alexandra Schrader, Nicole Weit, Rita Meister, Miriam Thiel, Tanja Annolleck, Anne Westermann, Till M Seiler, Thorsten Zenz, Jan Duerig, Jasmin Bahlo, Karl-Anton Kreuzer, Stephan Stilgenbauer, Anna-Maria Fink, Barbara Eichhorst, Michael Hallek, Marco Herling"]},"origin":[{"dateIssuedDisp":"2014","dateIssuedKey":"2014"}],"id":{"eki":["1505229804"]},"physDesc":[{"extent":"1 S."}],"relHost":[{"origin":[{"dateIssuedDisp":"1946-","publisher":"American Society of Hematology ; Saunders ; HighWire Press","dateIssuedKey":"1946","publisherPlace":"Washington, DC ; Philadelphia, Pa. ; Stanford, Calif."}],"id":{"zdb":["1468538-3"],"eki":["266886647"],"issn":["1528-0020"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Blood","title":"Blood","subtitle":"journal of the American Society of Hematology"}],"pubHistory":["1.1946 -"],"part":{"issue":"21","year":"2014","extent":"1","volume":"124","text":"124(2014,21) Artikel-Nr. 74529, 1 S."},"titleAlt":[{"title":"Blood online"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Induction treatment with alemtuzumab combined with polychemotherapy containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) followed by Alemtuzumab maintenance in patients with T-Cell prolymphocytic leukaemia (T-PLL) first analysis of a prospective multicenter phase-II-trial (T-PLL2) conducted by the German CLL study group (GCLLSG)Blood","note":["Gesehen am 21.04.2023"],"recId":"266886647","corporate":[{"roleDisplay":"Herausgebendes Organ","display":"American Society of Hematology","role":"isb"}],"language":["eng"]}]} | ||
| SRT | |a INDUCTIONT2014 | ||